REMEDi4ALL is pleased to announce that the MOI‑A study, one of the REMEDi4ALL demonstrator projects, is now actively recruiting patients across the UK and Europe. This clinical study is investigating whether losartan, a medicine widely used for high blood pressure, could be repurposed to benefit people living with Osteogenesis Imperfecta (OI) – a rare genetic condition characterised by fragile bones and frequent fractures.
The MOI‑A study aims to explore how losartan may reduce bone turnover by modulating TGFβ signalling and support effects on muscle strength and quality of life in adults and older adolescents with OI. By participating in this research, patients play a vital role in advancing knowledge and shaping future treatment options for their community.
Results and insights from the trial will contribute to the broader evidence base for drug repurposing and help inform future therapeutic strategies for rare diseases.
To find out more, read the full study publication: Matrix‑directed therapy losartan to identify the effect on the bone resorption marker CTX in older adolescents and adults with OI (BMJ Open) https://bmjopen.bmj.com/content/15/12/e107243
Watch our explainer video and learn how to get involved in the MOI‑A study:
The REMEDi4ALL Consortium, funded by a €25M grant from the European Commission under the Horizon Europe Programme, aims to facilitate a new generation of high quality, rigorous and patient-driven drug repurposing efforts across Europe.
